BioNTech Short Term Investments vs Total Current Liabilities Analysis
BNTX Stock | USD 100.34 1.47 1.44% |
BioNTech financial indicator trend analysis is way more than just evaluating BioNTech SE prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioNTech SE is a good investment. Please check the relationship between BioNTech Short Term Investments and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Short Term Investments vs Total Current Liabilities
Short Term Investments vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioNTech SE Short Term Investments account and Total Current Liabilities. At this time, the significance of the direction appears to have weak relationship.
The correlation between BioNTech's Short Term Investments and Total Current Liabilities is 0.38. Overlapping area represents the amount of variation of Short Term Investments that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of BioNTech SE, assuming nothing else is changed. The correlation between historical values of BioNTech's Short Term Investments and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Investments of BioNTech SE are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Short Term Investments i.e., BioNTech's Short Term Investments and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | 0.38 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Short Term Investments
Short Term Investments is an item under the current assets section of BioNTech balance sheet. It contains any investments BioNTech SE undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that BioNTech SE can easily liquidate in the marketplace.Total Current Liabilities
Total Current Liabilities is an item on BioNTech balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of BioNTech SE are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from BioNTech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At this time, BioNTech's Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.21 in 2024, whereas Tax Provision is likely to drop slightly above 243 M in 2024.
BioNTech fundamental ratios Correlations
Click cells to compare fundamentals
BioNTech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BioNTech fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 797.6M | 2.3B | 15.8B | 23.3B | 23.0B | 24.2B | |
Short Long Term Debt Total | 68.9M | 240.2M | 301.5M | 212.2M | 219.1M | 161.3M | |
Other Current Liab | 16.4M | 103.1M | 3.0B | 2.6B | 1.3B | 979.8M | |
Total Current Liabilities | 138.1M | 606.0M | 3.5B | 3.0B | 2.1B | 1.3B | |
Total Stockholder Equity | 493.5M | 1.4B | 11.9B | 20.1B | 20.2B | 21.3B | |
Other Liab | 205.6M | 97.1M | 109.7M | 283.9M | 326.5M | 166.9M | |
Net Tangible Assets | 179.6M | 406.5M | 1.2B | 11.7B | 13.5B | 14.1B | |
Property Plant And Equipment Net | 148.1M | 326.0M | 520.4M | 821.1M | 971.6M | 1.0B | |
Current Deferred Revenue | 93.6M | 391.5M | 189.1M | 77.1M | 353.3M | 371.0M | |
Net Debt | (450.2M) | (970.0M) | (1.4B) | (13.7B) | (11.4B) | (10.9B) | |
Retained Earnings | (424.8M) | (409.6M) | 9.9B | 18.8B | 19.8B | 20.8B | |
Accounts Payable | 20.5M | 102.3M | 160M | 204.1M | 354M | 371.7M | |
Cash | 519.1M | 1.2B | 1.7B | 13.9B | 11.7B | 12.2B | |
Non Current Assets Total | 237.5M | 651.7M | 758.5M | 1.4B | 3.5B | 3.7B | |
Non Currrent Assets Other | 2K | 1.0M | 800K | 6.5M | 83.4M | 87.6M | |
Other Assets | 2.4M | 168.2M | 22.2M | 249.2M | 286.6M | 300.9M | |
Long Term Debt | 68.9M | 231.0M | 171.6M | 176.2M | 191M | 116.1M | |
Cash And Short Term Investments | 520.8M | 1.3B | 2.1B | 14.1B | 16.5B | 17.4B | |
Net Receivables | 20.2M | 166.4M | 12.4B | 7.1B | 2.3B | 3.0B | |
Good Will | 3.0M | 53.7M | 57.8M | 61.2M | 362.5M | 380.6M | |
Common Stock Total Equity | 166.8M | 193.3M | 232.3M | 246.3M | 283.3M | 185.2M | |
Common Stock Shares Outstanding | 211.5M | 248.5M | 259.7M | 249.8M | 242.7M | 229.1M | |
Short Term Investments | 1.7M | 137.2M | 381.6M | 189.4M | 4.9B | 5.1B | |
Liabilities And Stockholders Equity | 797.6M | 2.3B | 15.8B | 23.3B | 23.0B | 24.2B | |
Non Current Liabilities Total | 166.0M | 340.8M | 455.5M | 272.9M | 689.9M | 378.2M | |
Inventory | 11.7M | 64.1M | 502.5M | 439.6M | 357.7M | 190.9M | |
Other Current Assets | 1.2M | 61.0M | 64.9M | 271.9M | 280.9M | 294.9M | |
Other Stockholder Equity | (5.5M) | 1.5B | (3.8M) | (5.3M) | 1.2B | 1.3B | |
Total Liab | 304.2M | 946.8M | 3.9B | 3.2B | 2.8B | 1.7B | |
Property Plant And Equipment Gross | 148.1M | 326.0M | 594.6M | 821.1M | 1.2B | 1.2B | |
Total Current Assets | 560.2M | 1.7B | 15.1B | 21.9B | 19.5B | 20.5B | |
Accumulated Other Comprehensive Income | 691.5M | 25.5M | 1.8B | 979.3M | (984.6M) | (935.4M) | |
Short Term Debt | 7.6M | 9.1M | 129.9M | 36M | 28.1M | 32.9M | |
Intangible Assets | 86.5M | 109.8M | 144.6M | 158.5M | 804.1M | 844.3M | |
Common Stock | 232.3M | 246.3M | 246.3M | 248.6M | 285.9M | 218.0M | |
Property Plant Equipment | 116.0M | 148.1M | 326.0M | 520.4M | 598.5M | 628.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.SGC | Superior Uniform Group | |
VLN | Valens | |
GNFT | Genfit |
Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.